Conference Day Two | Thursday 27th March, 2025

7:45 am Light Breakfast & Check-In

8:30 am Chair’s Opening Remarks

  • Chris Tame Chief Executive Officer, Ternary Therapeutics

Exploring Funding Challenges & Exciting Targets in the European TPD Space to Trailblaze the Path for Novel Therapeutics

8:45 am Characterizing Degradation Kinetics, Selectivity, & Cell-Specific Responses for Optimizing Therapeutic Efficacy of Degraders

9:15 am PANEL DISCUSSION Clear Skies or Stormy Seas: Sailing the European Markets in Search of Funding & Partnerships for Effective Degrader Development

  • Simon Glerup Chief Scientific Officer, Draupnir Bio
  • Kurt Pike Senior Director, Johnson & Johnson Innovation
  • Chris Tame Chief Executive Officer, Ternary Therapeutics

10:00 am Drugging the 14-3-3 Interactome – From Fragments to Cellular Function

  • Luc Brunsveld Professor of Chemical Biology, Eindhoven University of Technology & Co-Founder, Ambagon Therapeutics Inc

10:30 am Morning Break & Networking

For full session information,
download the brochure

DOWNLOAD NOW

Discovery Track

Leveraging Techniques for Warhead Discovery & Biological Validation of Novel Disease Targets to Unlock the Therapeutic Potential of Induced Proximity

Synopsis

Chair: Andrea Unzue Lopez, Head of TPD Chemistry, Merck Group

11:00 am From Ligases to Molecular Glues – Strategies to Discover Novel Molecular Glues

11:30 am The Power of Positive Selection in an E. coli Based Drug Discovery Engine for Induced Proximity Therapeutics

Pre-Clinical & Translation Track

New Frontiers in Targeted Degradation: Advancing Extracellular Matrix & Surface Protein Degraders for Expanding the Targetable Proteome & Curing Novel Diseases

Synopsis

Chair: William McEwan, Sir Henry Dale Fellow, UK Dementia Research Institute, University of Cambridge

11:00 am Harnessing Lysosomal Pathways for Effective Targeted Protein Degradation of Novel Targets to Cure Untreated Diseases

11:30 am SureTACsTM: Beyond Blocking Membrane Proteins

12:00 pm Lunch Break & Networking

Precision Protein Modulation: Promoting Diverse Pharmacologies to Expand the Therapeutic Potential of Induced Proximity Drugs

Synopsis

Chair: Jia Lu, Principal Scientist, Target Discovery, Phoremost

1:00 pm Non-Degrading Molecular Glues: A Platform for Finding Novel Chemical Matter for Inhibiting Intracellular & Transmembrane Proteins

  • Rick Ewing Vice President & Head of Chemistry, Rapafusyn Pharmaceuticals

1:30 pm ROUNDTABLE DISCUSSION: Discussing Challenges in the Mechanisms & Discovery of PROTACs & Molecular Glues

  • Rick Ewing Vice President & Head of Chemistry, Rapafusyn Pharmaceuticals

Overcoming Clinical Hurdles & Advancing Computational Strategies for Degrader Success

Synopsis

Chair: Andrea Unzue Lopez, Head of TPD Chemistry, Merck Groupr:

1:00 pm Leveraging Computational Approaches for the Discovery & Optimisation of Molecular Glues

  • Chris Tame Chief Executive Officer, Ternary Therapeutics

1:30 pm ROUNDTABLE DISCUSSION: Utilizing Pre-Clinical Data to Predict the Right Dosing Regimen for Your TPD Drug

  • Chinatsu Sakata-Sakurai Vice-President, Primary Focus Lead, Targeted Protein Degradation, Astellas Pharma
  • Kevin Wilson Vice President & Head of Chemistry, Foghorn Therapeutics

For full session information,
download the brochure

DOWNLOAD NOW

2:00 pm Afternoon Break & Networking

Overcoming Challenges in the Development of Degraders Against Diseases Beyond Oncology to Benefit a Whole New Class of Patients

3:00 pm Elucidating the Discovery of TRIM21 & the Development of Targeted Degraders Against it to Cure Neurodegenerative Diseases

  • William Mcewan Sir Henry Dale Fellow, UK Dementia Research Institute, University of Cambridge
  • Andrea Testa Senior Director of Chemistry, Trimtech Therapeutics

4:00 pm Exploring the Current Landscape & Future Outlook of the TPD Non-Oncology Space

4:30 pm Chair’s Closing Remarks

4:45 pm End of Day Two & the 5th TPD & Induced Proximity Summit Europe

EVENT GUIDE
REGISTER
PARTNER